SILO Pharma Inc

NASDAQ: SILO    
Share price (5/2/24): $1.85    
Market cap (5/2/24): $5.261 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 2 pages Third Amendment to Master License Agreement
12/34/56
EX-10.3
from 8-K 1 page First Amendment to Employment Agreement
12/34/56
EX-10.2
from 8-K 16 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 2 pages [*] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. First Amendment to Sponsored Research Agreement
12/34/56
EX-10.1
from 8-K 8 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 16 pages [*] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Sponsored Research Agreement
12/34/56
EX-10.1
from 8-K 7 pages Stock Purchase Agreement
12/34/56
EX-10.2
from 8-K 2 pages First Amendment to Commercial Evaluation and License Agreement
12/34/56
EX-10.1
from 8-K 17 pages [*] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Sponsored Research Agreement
12/34/56
EX-10.1
from 8-K 8 pages [*] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Sponsored Research Agreement
12/34/56
EX-10.1#
from 8-K 9 pages [*] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Joint Venture Agreement
12/34/56
EX-10.1
from 8-K 3 pages Amendment No. 1 to Patent License Agreement
12/34/56
EX-10.1
from 8-K 34 pages [*] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Sublicense Agreement
12/34/56
EX-10.2
from 8-K 2 pages [*] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.1
from 8-K 51 pages Master License Agreement Between University of Maryland, Baltimore and SILO Pharma, Inc. Ott Docket No.: Km-2016-101
12/34/56
EX-10.5
from 8-K/A 18 pages Placement Agent Common Stock Purchase Warrant SILO Pharma, Inc
12/34/56
EX-10.4
from 8-K 2 pages Lock-Up Agreement
12/34/56
EX-10.3
from 8-K 27 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 18 pages Common Stock Purchase Warrant SILO Pharma, Inc
12/34/56
EX-10.1
from 8-K 45 pages Securities Purchase Agreement
12/34/56